drugset / Trial / NCT03736772
A Study of LY3090106 in Japanese and Caucasian Healthy Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to evaluate the safety of a study drug known as LY3090106 in healthy Caucasian and Japanese participants. Side effects and tolerability will be documented. Blood samples will be taken to compare how the body handles the drug. The study will last about 12 weeks, not including screening or additional follow-up.
Timeline
- Start
- 2018-11-19
- Primary completion
- 2019-03-13
- Completion
- 2019-03-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tibulizumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.